<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0f740c03-989d-446a-b0e4-3ef268d2dff1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Desoximetasone Ointment USP, 0.25% </content>
   </title>
   <effectiveTime value="20240312"/>
   <setId root="2a59a313-efd8-4377-bd41-caeeffa79775"/>
   <versionNumber value="102"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-1414"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-1414"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e26ebccc-ae7c-48b3-9de6-52eddc2d08cf"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240312"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72162-1414" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>desoximetasone</name>
                        <formCode code="C42966" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OINTMENT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Desoximetasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="45802-496" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DESOXIMETASONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DESOXIMETASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PETROLATUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72162-1414-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230817"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72162-1414-6" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230817"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077770" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150514"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="dc34efdb-8c16-4eb2-8da4-bd026fa4e93e">
                     <text>Image 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_77da1657-2ea4-4030-9950-145c3b2ab11c">
               <id root="dee0bd59-2878-4c29-88a0-98a32fa28643"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">For Topical Use Only. Not For Oral, Ophthalmic, or Intravaginal Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230817"/>
            </section>
         </component>
         <component>
            <section ID="ID_b0999811-3ffb-4385-a7b3-bdbdea65317d">
               <id root="00929d84-5a0a-47d7-a554-005b2b614acc"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.</paragraph>
                  <paragraph>Each gram of Desoximetasone Ointment USP, 0.25% contains 2.5 mg of desoximetasone in an ointment base consisting of fractionated coconut oil and white petrolatum.</paragraph>
                  <paragraph>The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11β,16α)-.Desoximetasone has the molecular formula C<sub>22</sub>H<sub>29</sub>FO<sub>4</sub> and a molecular weight of 376.47. The CAS Registry Number is 382-67-2.</paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <renderMultiMedia ID="id2129119401" referencedObject="dc34efdb-8c16-4eb2-8da4-bd026fa4e93e"/>
               </text>
               <effectiveTime value="20220408"/>
            </section>
         </component>
         <component>
            <section ID="ID_8f6605ac-a072-45d7-8695-272e920f1ec0">
               <id root="5366dd3d-2612-4ff4-a569-ae6defe9aae2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.</paragraph>
                  <paragraph>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.</paragraph>
               </text>
               <effectiveTime value="20130708"/>
               <component>
                  <section ID="ID_2c44e300-9c91-4210-9911-a38ea85ad214">
                     <id root="2270e175-6a65-4b28-9b0d-be75ecc55056"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics -</title>
                     <text>
                        <paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.</paragraph>
                        <paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                        <paragraph>Pharmacokinetic studies in men with Desoximetasone Ointment USP, 0.25% with tagged desoximetasone showed no detectable level (limit of sensitivity: 0.003 μg/mL) in 1 subject and 0.004 and 0.006 μg/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces. Seven days after application, no further radioactivity was detected in urine or feces. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4206fd55-bd4a-4fae-8c34-e3c70db4b3df">
               <id root="68593c3d-205b-460f-9c68-e6b60b81438f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Desoximetasone Ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_8c1401b3-9482-49e6-bf9b-3be057b1567b">
               <id root="5a980549-fd14-4cb9-a02c-ee25434cbb5f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Desoximetasone ointment USP, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.</paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_a1416a38-dad9-45b5-9303-0230bdca7f7c">
               <id root="dd70faa8-6c86-49c4-868f-3f4f1f75a126"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Keep out of reach of children.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_d6341c20-3cef-4156-a727-6e819b117a2e">
               <id root="9f166966-735b-4101-9cf0-5abcd3c5128f"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20220408"/>
               <component>
                  <section ID="ID_ff08391c-ba5e-49c5-9308-19a6f9cc6b4a">
                     <id root="a7a537bb-3541-4e79-a695-56b6a0d715d1"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General -</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.</paragraph>
                        <paragraph>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.</paragraph>
                        <paragraph>An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.</paragraph>
                        <paragraph>Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.</paragraph>
                        <paragraph>Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.</paragraph>
                        <paragraph>Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c9a3e2d-e4cf-4f15-931e-ebe5750d002c">
                     <id root="129cd18d-1ace-44b8-a547-f197fc4cd92c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Local Adverse Reactions with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bfab32c0-6625-4eaf-98f7-0370bdfb0648">
                     <id root="b41e773f-13fb-46a9-a6ee-9bab5c0c79e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Allergic Contact Dermatitis with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.</paragraph>
                     </text>
                     <effectiveTime value="20220408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_383eda19-e13d-432d-bd54-99c1cdde3a63">
                     <id root="e146da0a-61dd-4ad0-b6f8-f2a8e3c800a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Concomitant skin infections should be treated with an appropriate antimicrobial agent.</paragraph>
                        <paragraph>If the infection persists, desoximetasone ointment USP, 0.25% should be discontinued until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04e39145-1fcc-4eb5-adcb-9ded6120d1d9">
                     <id root="4d841018-a1c8-43ba-a98e-46b50ce69fc9"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</item>
                           <item>
                              <caption>2.</caption>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</item>
                           <item>
                              <caption>3.</caption>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</item>
                           <item>
                              <caption>4.</caption>Patients should report any signs of local adverse reactions, especially under occlusive dressings.</item>
                           <item>
                              <caption>5.</caption>Other corticosteroid-containing products should not be used with desoximetasone ointment USP, 0.25% without first consulting with the physician. As with other corticosteroids, therapy should be discontinued when control is achieved.<paragraph>If no improvement is seen within 4 weeks, contact the physician.</paragraph>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20220408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a4a84dc4-8360-4e5a-a425-c82889708b82">
                     <id root="287fac3f-d20d-4e26-8e39-930de75efb11"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>The following tests may be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis suppression:</paragraph>
                        <paragraph>     Urinary free cortisol test</paragraph>
                        <paragraph>     ACTH stimulation test</paragraph>
                     </text>
                     <effectiveTime value="20220408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_72e08204-e150-49f9-ba62-1888595ac119">
                     <id root="8345a563-4ffb-42f2-bd4a-0809f5d22c99"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Desoximetasone was nonmutagenic in the Ames test.</paragraph>
                     </text>
                     <effectiveTime value="20220408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b531b095-28b9-4a36-a178-3b7698a44430">
                     <id root="2c3d9753-cb47-4eb4-9ff8-1c1bcf3cefae"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy. Teratogenic Effects. Pregnancy Category C</title>
                     <text>
                        <paragraph>Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</paragraph>
                        <paragraph>Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone ointment USP, 0.25%</paragraph>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone ointment USP, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph>
                     </text>
                     <effectiveTime value="20220408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_32b6c272-148b-4e1e-a223-a8cbda63792f">
                     <id root="46da8a40-7573-493a-bca3-cd0ee70cf79e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers -</title>
                     <text>
                        <paragraph>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_07fa0d06-5cd5-4af7-9cd1-c2de36c9ab06">
                     <id root="b4d523a2-e176-47b6-9258-f553030db74a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use -</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.</content>
                        </paragraph>
                        <paragraph>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients. Safety and effectiveness of Desoximetasone Ointment USP, 0.25% in pediatric patients below the age of 10 have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20130708"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8f59c478-269a-471c-bd3a-3399bcb7dd6e">
               <id root="6eac788c-4438-4880-a503-448547f88954"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings.</paragraph>
                  <paragraph>These reactions are listed in an approximate decreasing order of occurrence:</paragraph>
                  <table width="100%">
                     <col width="12%"/>
                     <col width="29%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr styleCode="Toprule">
                           <td valign="top">
                              <paragraph>Burning</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Hypertrichosis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Maceration of the skin</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Itching</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Acneiform eruptions</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Secondary infection</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Irritation</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Hypopigmentation</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Skin atrophy</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Dryness</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Perioral dermatitis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Striae</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td valign="top">
                              <paragraph>Folliculitis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Allergic contact dermatitis</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Milaria</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In controlled clinical studies the incidence of adverse reactions was low (0.3%) for Desoximetasone Ointment USP, 0.25% and consisted of development of comedones at the site of application.</paragraph>
               </text>
               <effectiveTime value="20220408"/>
            </section>
         </component>
         <component>
            <section ID="ID_df1ccae6-466a-4b4b-9841-3bebf1af8952">
               <id root="dcf40dda-de08-4c8b-bc64-1b532e17c635"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <content styleCode="bold">PRECAUTIONS</content>).</paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_4f9de1d5-af53-46b3-bb81-983e440555a5">
               <id root="9757e206-9efe-43cd-8830-35f57b27c1ee"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply a thin film of Desoximetasone Ointment USP, 0.25% to the affected skin areas twice daily. Rub in gently.</paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_cc167779-acbb-4e8a-a079-e5b019a964bd">
               <id root="da1f3ccf-c694-46ea-8fcf-5a49ae62d280"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Desoximetasone Ointment USP, 0.25%</content> is supplied as follows:</paragraph>
                  <paragraph>15 gram tube (NDC 72162-1414-2)</paragraph>
                  <paragraph>60 gram tube (NDC 72162-1414-6)</paragraph>
                  <paragraph>Repackaged/Relabeled by:</paragraph>
                  <paragraph>Bryant Ranch Prepack, Inc.</paragraph>
                  <paragraph>Burbank, CA 91504</paragraph>
               </text>
               <effectiveTime value="20240312"/>
            </section>
         </component>
         <component>
            <section ID="ID_0647552a-0cb9-42bc-a1f7-89a51adfa256">
               <id root="245bfce2-69f3-4670-8ad0-7e4738c7fb2e"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <text>
                  <paragraph>Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20130708"/>
            </section>
         </component>
         <component>
            <section ID="ID_4e9a9a18-11c9-480c-8f90-bf0db7fb2513">
               <id root="c973bcd1-4d37-4a00-8528-39e6c4f68f12"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Made in Israel</paragraph>
                  <paragraph>Manufactured By Perrigo, Yeruham, Israel</paragraph>
                  <paragraph>Distributed By Perrigo, Allegan, MI 49010 • www.perrigo.com</paragraph>
                  <paragraph>Rev 03-20</paragraph>
                  <paragraph>4N400 RC J3</paragraph>
               </text>
               <effectiveTime value="20220408"/>
            </section>
         </component>
         <component>
            <section>
               <id root="7132d975-068a-4570-b7c7-a03c46faff56"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Desoximetasone 0.25% Ointment</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="mm63629"/>
               </text>
               <effectiveTime value="20230817"/>
               <component>
                  <observationMedia ID="mm63629">
                     <text>Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl721621414.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>